The guidance cut signals slower-than-expected U.S. commercial ramp, which is the primary revenue growth driver. Watch for Q4 2026 actual revenue and the FDA's decision on the PMA supplement for CCC indication expansion, which could be a catalyst if approved.
Price Chart
Executive Summary
Nyxoah reported preliminary Q3 2026 global net revenue of €9.2M (19% sequential growth) and U.S. net revenue of €6.7M (29% sequential growth), but lowered full-year 2026 revenue guidance to €33-35M from €36-40M. The EPS miss of -82.3% versus consensus (-$0.58 actual vs -$0.32 estimate) and the guidance cut are the dominant negative signals, despite sequential revenue acceleration and a PMA supplement submission to expand Genio's U.S. indication.
Key Financial Metrics
Key Facts
- Q3 2026 preliminary global net revenue of €9.2M, up 19% sequentially from Q2 2026
- U.S. net revenue of €6.7M, up 29% sequentially from Q2 2026
- Full-year 2026 revenue guidance lowered to €33-35M from prior €36-40M
- EPS of -$0.58 missed consensus of -$0.32 by 82.3%
- Cash, cash equivalents and financial assets of ~€77.0M as of Sep 30, 2026
- PMA supplement submitted to FDA to expand Genio's U.S. indication to Complete Concentric Collapse patients
- 80 new surgeons trained in Q3 (total 342); 53 new accounts activated (total 233 active high-volume accounts)
- 447 patients actively under prior authorization entering Q4
Financial Impact
Revenue guidance cut by ~€4M at midpoint (€34M vs prior €38M); EPS miss of -$0.26 vs consensus
Risk Factors
- Lowered full-year guidance indicates slower U.S. adoption than previously expected
- EPS miss of 82.3% vs consensus is a significant negative surprise
- Preliminary results are subject to revision upon full Q3 2026 filing
- Dependence on FDA approval for CCC indication expansion to drive future growth
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383354 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $0.8950 $0.8220 | ▲ +8.16% | ▲ +6.98% | $0.8560 (+4.36%) |
Oct 19, 2026 7d ago | Press Release | $0.9540 $0.9400 | ▲ +1.47% | ▲ +1.80% | $0.8560 (+10.27%) |
Sep 22, 2026 4w ago | 6-K | $1.33 $1.27 | ▼ −4.51% | ▼ −4.43% | $0.8560 (−35.64%) |
Jun 23, 2026 17w ago | 6-K | $1.62 $1.63 | ▼ −0.62% | ▼ −0.47% | $0.8560 (+47.16%) |
Jun 11, 2026 19w ago | 6-K | $1.39 $1.55 | ▼ −11.51% | ▼ −9.75% | $0.8560 (+38.42%) |
Jun 8, 2026 20w ago | 6-K | $1.34 $1.31 | ▲ +2.24% | ▲ +0.66% | $0.8560 (+36.12%) |
Jun 8, 2026 20w ago | 424B5 | $1.39 $1.34 | ▲ +3.60% | ▲ +3.30% | $0.8560 (+38.42%) |
Jun 5, 2026 20w ago | Press Release | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
Jun 4, 2026 20w ago | 424B5 | $1.45 $1.39 | ▲ +4.14% | ▲ +4.36% | $0.8560 (+40.97%) |
May 20, 2026 22w ago | Press Release | $2.87 $2.87 | · 0.00% | ▼ −0.45% | $0.8560 (−70.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers